Daiichi Sankyo Company, Limited (DSKYF)
- Zacks
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
- Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated wi
- Zacks
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
